Toru Ichinose

587 total citations
11 papers, 413 citations indexed

About

Toru Ichinose is a scholar working on Genetics, Oncology and Immunology. According to data from OpenAlex, Toru Ichinose has authored 11 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Oncology and 6 papers in Immunology. Recurrent topics in Toru Ichinose's work include Virus-based gene therapy research (8 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (4 papers). Toru Ichinose is often cited by papers focused on Virus-based gene therapy research (8 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (4 papers). Toru Ichinose collaborates with scholars based in Japan, Egypt and United States. Toru Ichinose's co-authors include Hideki Kasuya, Maki Tanaka, Yoshinori Naoe, Yasuhiro Kodera, Nobuaki Mukoyama, Ibrahim Ragab Eissa, Noriyuki Miyajima, Zhiwen Wu, Branko Aleksić and Seiji Sumigama and has published in prestigious journals such as Science Translational Medicine, International Journal of Cancer and Cells.

In The Last Decade

Toru Ichinose

11 papers receiving 398 citations

Peers

Toru Ichinose

ONCOL

GENET

IMMUN

BIOTE

Adina Pelusio South Korea

Naomi De Silva Canada

Ibrahim Ragab Eissa Japan

Laetitia Fend France

Shohei Miyamoto Japan

Janet Lei-Rossmann United Kingdom

Amelia S. Aitken Canada

Petri Nokisalmi Finland

Kathryn Ottolino‐Perry Canada

Louise Medley United Kingdom

Adina Pelusio South Korea

Toru Ichinose

233 ×0.8

ONCOL

232 ×0.9

GENET

88 ×0.6

102 ×1.1

IMMUN

56 ×0.7

BIOTE

Citations per year, relative to Toru Ichinose Toru Ichinose (= 1×) peers Adina Pelusio

Countries citing papers authored by Toru Ichinose

Since Specialization

Citations

This map shows the geographic impact of Toru Ichinose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toru Ichinose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toru Ichinose more than expected).

Fields of papers citing papers by Toru Ichinose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toru Ichinose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toru Ichinose. The network helps show where Toru Ichinose may publish in the future.

Co-authorship network of co-authors of Toru Ichinose

This figure shows the co-authorship network connecting the top 25 collaborators of Toru Ichinose. A scholar is included among the top collaborators of Toru Ichinose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toru Ichinose. Toru Ichinose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Matsumura, Shigeru, Toru Ichinose, Ibrahim Ragab Eissa, et al.. (2024). STING activator 2′3′‐cGAMP enhanced HSV‐1‐based oncolytic viral therapy. Molecular Oncology. 18(5). 1259–1277. 7 indexed citations

Kanaya, Nobuhiko, Yohei Kitamura, Kok‐Siong Chen, et al.. (2023). Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas. Science Translational Medicine. 15(698). eade8732–eade8732. 13 indexed citations

Miyajima, Noriyuki, Ibrahim Ragab Eissa, Yoshinori Naoe, et al.. (2021). S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.. PubMed. 83(4). 683–696. 2 indexed citations

Eissa, Ibrahim Ragab, Nobuaki Mukoyama, Yoshinori Naoe, et al.. (2021). Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8⁺PD‐1⁻ tumor‐infiltrating T cells in PD‐L1‐enriched tumor microenvironment. International Journal of Cancer. 149(1). 214–227. 17 indexed citations

Matsumura, Shigeru, Toru Ichinose, Yoshinori Naoe, et al.. (2021). C-REV Retains High Infectivity Regardless of the Expression Levels of cGAS and STING in Cultured Pancreatic Cancer Cells. Cells. 10(6). 1502–1502. 8 indexed citations

Wu, Zhiwen, Toru Ichinose, Yoshinori Naoe, et al.. (2019). Combination of Cetuximab and Oncolytic Virus Canerpaturev Synergistically Inhibits Human Colorectal Cancer Growth. Molecular Therapy — Oncolytics. 13. 107–115. 25 indexed citations

Hirooka, Yoshiki, Hideki Kasuya, Takuya Ishikawa, et al.. (2018). A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer. 18(1). 596–596. 110 indexed citations

Eissa, Ibrahim Ragab, Toru Ichinose, Shigeru Matsumura, et al.. (2018). The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. Cancers. 10(10). 356–356. 121 indexed citations

Hotta, Yoshihiro, Hideki Kasuya, Yoshinori Naoe, et al.. (2017). Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity. PubMed. Volume 6. 31–38. 10 indexed citations

10.

Eissa, Ibrahim Ragab, Yoshinori Naoe, Toru Ichinose, et al.. (2017). Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials. Frontiers in Oncology. 7. 149–149. 78 indexed citations

11.

Ichinose, Toru. (2013). Evaluation of antiviral activity of Oligonol, an extract of Litchi chinensis, against betanodavirus. Drug Discoveries & Therapeutics. 7(6). 254–60. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact